Table of Contents
ISRN Pharmacology
Volume 2012, Article ID 782656, 10 pages
http://dx.doi.org/10.5402/2012/782656
Research Article

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

1Clinical Pharmacology, Janssen Research & Development, L.L.C., 920 Route 202, Raritan, NJ 08869, USA
2Clinical Research and Public Policy, School of Pharmacy, Virginia Commonwealth University, MCV Campus, 215 McGuire Hall, 1112 East Clay Street, P.O. Box 980533, Richmond, VA 23298, USA
3Clinical Development, Janssen Research & Development, L.L.C, 6500 Paseo Padre Parkway, B-1, Fremont, CA 94555, USA
4Clinical Pharmacology, Janssen Research & Development, L.L.C., 1125 Trenton-Harbourton Road, Titusville, NJ 08650, USA

Received 17 April 2012; Accepted 30 May 2012

Academic Editors: M. Brunner, K. Cimanga, and H. Kankaanranta

Copyright © 2012 Mahesh N. Samtani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Mahesh N. Samtani, Nicole Vaccaro, Iolanda Cirillo, Gary R. Matzke, Rebecca Redman, and Partha Nandy, “Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy,” ISRN Pharmacology, vol. 2012, Article ID 782656, 10 pages, 2012. https://doi.org/10.5402/2012/782656.